RNF20

Across TCGA pan-cancer cohorts, RNF20 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RNF20 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNF20 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RNF20 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where RNF20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.899	0.261	.006	9	view →
LSCC	DFS	Median	All	0.798	0.621	.018	6	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	3	view →
GBM	OS	Median	All	0.609	0.268	.022	2	view →
HNSC	DFS	Median	III,IV	0.700	0.870	.025	2	view →
PDAC	DFS	Median	II,III,IV	0.863	0.689	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNF20–LUAD (DFS)

Open the LUAD breakdown →